# US 2010/0167296 A1 · Method of determining a chemotherapeutic regime and survival expectancy for non small cell lung cancer based on egfr/csf-1/ca ix expression > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2010/0167296 A1 - Document ID: US20100167296A1 - Status: Published application - Kind: A1 - Application number: 12/594,914 - Filed: 2008-04-11 - Published: 2010-07-01 - Earliest claimed: 2007-04-13 - Assignees: Pangaea Biotech, S.A. - Inventors: Rafael Rosell Costa; Miguel Taron Roca - Web page: https://patentgrep.com/patent/US20100167296A1 ## CPC - G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells} - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - G01N 33/5752: of the lungs - C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism - C12Q 2600/118: Prognosis of disease development - G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis - G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q) - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES ## Abstract The present invention relates to a screening method for classifying and for deciding to apply chemotherapy to patients suffering from non-small-cell lung cancer (NSCLC), based on detecting the levels of EGFR, CSF-1 and CA IX. ## Claims ### Claim 1 A method for predicting the survival of a patient suffering from non-small-cell lung cancer (NSCLC), comprising the steps of: a) isolating mRNA from a tumor sample of the patient; b) determining the gene expression levels of EGFR, CSF-1 and CA IX genes in the sample; and c) comparing the expression levels of EGFR, CSF-1 and CA IX genes in the sample with reference values for EGFR, CSF-1 and CA IX expression levels, wherein an increased expression of the EGFR and CSF-1 genes and a decreased expression of the CA IX gene with respect to the reference values is indicative that the survival prognosis of said patient will be decreased with respect to patients wherein expression of the EGFR, CSF-1 and CA IX gene is not altered. ### Claim 2 (depends on 1) The method of claim 1, which further comprises: detecting in step (b) the expression levels of one or more additional genes selected from the group of fibronectin 1 (FN1), insulin receptor 1 (ISNR), anillin (ANLN), prolyl hydrolase 4 (PH4), VEGF-C, NTRK1 and KIAA0974; and comparing in step (c) the expression levels of the additional gene or genes with reference values for the expression levels of said genes, wherein an increased expression of any of said genes with respect to the reference value in combination with an increased expression EGFR, CSF-1 and a decreased expression of CA IX is indicative that the survival prognosis of said patient will be decreased with respect to patients wherein expression of the same genes is not altered. ### Claim 3 A method for predicting the survival of a patient suffering from non-small-cell lung cancer (NSCLC), comprising the steps of: a) isolating mRNA from a tumor sample of the patient; b) determining the gene expression level of EGFR, CSF-1 and CA IX genes in the sample; and c) calculating a risk score on the basis of the expression levels of EGFR, CSF-1 and CA IX genes using the formula [0.93×CSF+1.4×CA IX+1.1×EGFR] wherein CSF, CA IX and EGFR are the z-scores of the expression levels of the CSF-1, CA IX and EGFR genes, wherein a risk score higher than 0 is indicative of poor survival. ### Claim 4 (depends on 1) A method according to claim 1, wherein the NSCLC is squamous cell carcinoma. ### Claim 5 (depends on 1) A method according to claim 1, wherein the NSCLC patient is a stage IA, IB or stage II patient. ### Claim 6 A method for deciding whether a patient suffering NSCLC should be treated with chemotherapy, which comprises the steps of: a) isolating mRNA from a tumor sample of the patient; b) determining the gene expression level of EGFR, CSF-1 and CA IX genes in the sample; and c) comparing the expression levels of EGFR, CSF-1 and CA IX genes in the sample with reference values for EGFR, CSF-1 and CA IX expression levels, wherein an increased expression of the EGFR and CSF-1 genes and a decreased expression of the CA IX gene with respect to the reference values is indicative that the patient should be treated with chemotherapy. ### Claim 7 A method for deciding whether a patient suffering NSCLC should be treated with chemotherapy, comprising the steps of: a) isolating mRNA from a tumor sample of the patient; b) determining the gene expression level of EGFR, CSF-1 and CA IX genes in the sample; and c) calculating a risk score on the basis of the expression levels of EGFR, CSF-1 and CA IX genes using the formula [0.93×CSF+1.4×CA IX+1.1×EGFR] wherein CSF, CA IX and EGFR are the z-scores of the expression levels of the CSF-1, CA IX and EGFR genes, wherein a risk score higher than 0 is indicative that the patient should be treated with chemotherapy. ### Claim 8 (depends on 6) A method according to claim 6, wherein the NSCLC patient is a stage I or stage II patient. ### Claim 9 A kit for detecting altered expression of the genes EGFR, CSF-1 and CA IX, which comprises a first pair of primers which is capable of amplifying a region of EGFR, a second pair of primers which is capable of amplifying a region of CSF-1, and a third pair of primers which is capable of amplifying a region of the CA IX gene. ### Claim 10 (depends on 9) A kit according to claim 9, which further comprises at least a pair of primers capable of amplifying a region of a gene selected from the group consisting of FN1, ISNR, ANLN, PH4, VEGF-C, NTRK1 and KIAA0974. ### Claim 11 (depends on 9) A kit according to claim 9, which further comprises a reverse transcriptase. ### Claim 12 (depends on 9) A method for predicting the survival of a patient suffering from NSCLC, comprising detecting altered expression of the genes EGFR, CSF-1 and CA IX in said patient, by use of a kit as claimed in claim 9. ### Claim 13 (depends on 9) A method for deciding whether a patient suffering NSCLC should be treated with chemotherapy, comprising detecting altered expression of the genes EGFR, CSF-1 and CA IX in said patient, by use of a kit as claimed in claim 9. ### Claim 14 (depends on 7) A method according to claim 7, wherein the NSCLC patient is a stage I or stage II patient. ### Claim 15 (depends on 10) A kit according to claim 10, which further comprises a reverse transcriptase.